Microsatellites as EWS/FLI response elements in Ewing's sarcoma
Open accessThe DOI matches its Crossref record; 29 of the 30 references it cites were found in a registry or an index.
Abstract
The ETS gene family is frequently involved in chromosome translocations that cause human cancer, including prostate cancer, leukemia, and sarcoma. However, the mechanisms by which oncogenic ETS proteins, which are DNA-binding transcription factors, target genes necessary for tumorigenesis is not well understood. Ewing's sarcoma serves as a paradigm for the entire class of ETS-associated tumors because nearly all cases harbor recurrent chromosomal translocations involving ETS genes. The most common translocation in Ewing's sarcoma encodes the EWS/FLI oncogenic transcription factor. We used whole genome localization (ChIP-chip) to identify target genes that are directly bound by EWS/FLI. Analysis of the promoters of these genes demonstrated a significant over-representation of highly repetitive GGAA-containing elements (microsatellites). In a parallel approach, we found that EWS/FLI uses GGAA microsatellites to regulate the expression of some of its target genes including NR0B1 , a gene required for Ewing's sarcoma oncogenesis. The microsatellite in the NR0B1 promoter bound EWS/FLI in vitro and in vivo and was both necessary and sufficient to confer EWS/FLI regulation to a reporter gene. Genome wide computational studies demonstrated that GGAA microsatellites were enriched close to EWS/FLI-up-regulated genes but not down-regulated genes. Mechanistic studies demonstrated that the ability of EWS/FLI to bind DNA and modulate gene expression through these repetitive elements depended on the number of consecutive GGAA motifs. These findings illustrate an unprecedented route to specificity for ETS proteins and use of microsatellites in tumorigenesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Nine ETS proteins have been assayed for genome-wide occupancy by either promoter microarrays (ETS1, GABPA, ELF1, ELK1, EWS-FLI1, and SPI1) (132–135) or high-throughput sequencing (GABPA, ETS1, ERG, FLI1, EWS-ERG, EWS-FLI1, SPI1, SPDEF, ETV1, and ELF1) (29, 62, 65, 136–140).”
From Genomic and biochemical insights into the specificity of ETS transcription factors (2011) · cites this paper as [133]
In the citing paper
“Of these two classes of target sequences, only genes near the microsatellite repeats correlate with expression changes associated with transformation, including NROB1 (133) and GSTM4 (186).”
From Genomic and biochemical insights into the specificity of ETS transcription factors (2011) · cites this paper as [133]
In the citing paper
“ChIP-chip and ChIP-Seq have identified the genomic regions bound by the most common ETS fusion proteins in Ewing’s sarcoma, EWS-FLI1 and EWS-ERG (62, 133, 137).”
From Genomic and biochemical insights into the specificity of ETS transcription factors (2011) · cites this paper as [133]
In the citing paper
“In fact, four or more repeats are necessary for EWS-FLI1 transcriptional activation in reporter assays, and two EWS-FLI1 monomers bind to this four-motif array in biochemical assays (Figure 7) (133, 137, 187).”
From Genomic and biochemical insights into the specificity of ETS transcription factors (2011) · cites this paper as [133]
Citations
Cites
Fitting a mixture model by expectation maximization to discover motifs in biopolymers.
Bailey, T. L., & Elkan, C. (1994) · PubMed · Cited by 5,806
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., et al. (2005) · Science · doi:10.1126/science.1117679 · Cited by 3,846
Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995
US Department of Health and Human Services; National Cancer Institute (1999) · PsycEXTRA Dataset · doi:10.1037/e407432005-001 · Cited by 1,947
Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours
Delattre, O., Zucman, J., Plougastel, B., Desmaze, C., Melot, T., Peter, M., Kovar, H., Joubert, I., de Jong, P., Rouleau, G., et al. (1992) · Nature · doi:10.1038/359162a0 · Cited by 1,907 · cited 2×
“Ewing’s sarcoma is a highly malignant solid tumor of children and young adults that usually harbors a recurrent chromosomal translocation, t(11;22)(q24;q12), that encodes the EWS/FLI fusion oncoprotein (10).”
BackgroundThe ETS-domain transcription factor family
Sharrocks, A. D. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35099076 · Cited by 1,086 · cited 1×
“Most members of the ETS family bind to DNA sequences containing a GGAA (or in some cases, GGAT) core motif, with sequences flanking the GGAA core contributing to the affinity and specificity of the interaction (3, 6, 7).”
BackgroundCentre d'Etude du polymorphisme humain (CEPH): Collaborative genetic mapping of the human genome
Dausset, J., Cann, H., Cohen, D., Lathrop, M., Lalouel, J.-M., & White, R. (1990) · Genomics · doi:10.1016/0888-7543(90)90491-c · Cited by 575
May, W. A., Gishizky, M. L., Lessnick, S. L., Lunsford, L. B., Lewis, B. C., Delattre, O., Zucman, J., Thomas, G., & Denny, C. T. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.12.5752 · Cited by 574
Self-citationMay, W. A., Lessnick, S. L., Braun, B. S., Klemsz, M., Lewis, B. C., Lunsford, L. B., Hromas, R., & Denny, C. T. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.12.7393 · Cited by 497
Self-citationETS transcription factors and their emerging roles in human cancer
Seth, A., & Watson, D. K. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.08.013 · Cited by 469
TMPRSS2:ETV4 Gene Fusions Define a Third Molecular Subtype of Prostate Cancer
Tomlins, S. A., Mehra, R., Rhodes, D. R., Smith, L. R., Roulston, D., Helgeson, B. E., Cao, X., Wei, J. T., Rubin, M. A., Shah, R. B., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0168 · Cited by 469
Research works printed but not linked: 2
- 10.1128/mcb.13.12.7393-7398.1993 · doi:10.1128/mcb.13.12.7393-7398.1993 · Paper page
- ME Gillespie A structural and genetic investigation of DNA binding by the murine Ets-1 Ets domain a winged HTH transcription factor. (University of Utah Salt Lake City PhD thesis. (1998).
Cited by
Items 101–200 of 298
Dysregulated heparan sulfate proteoglycan metabolism promotes Ewing sarcoma tumor growth
Vasileva, E., Warren, M., Triche, T. J., & Amatruda, J. F. (2022) · eLife · doi:10.7554/elife.69734 · Cited by 41
The Role of Phase-Separated Condensates in Fusion Oncoprotein–Driven Cancers
Shirnekhi, H. K., Chandra, B., & Kriwacki, R. W. (2023) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-061421-122050 · Cited by 39
McBride, M. J., & Kadoch, C. (2018) · The Journal of Pathology · doi:10.1002/path.5042 · Cited by 45
Ehrlund, A., & Treuter, E. (2011) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2011.04.007 · Cited by 43
Catalytic inhibition of KDM1A in Ewing sarcoma is insufficient as a therapeutic strategy
Romo‐Morales, A., Aładowicz, E., Blagg, J., Gatz, S. A., & SHIPLEY, J. M. (2019) · Pediatric Blood & Cancer · doi:10.1002/pbc.27888 · Cited by 39
Review: Ewing Sarcoma Predisposition
Gargallo, P., Yáñez, Y., Juan, A. D., Segura, V., Balaguer, J., Torres, B., Oltra, S., Castel, V., & Cañete, A. (2019) · Pathology & Oncology Research · doi:10.1007/s12253-019-00765-3 · Cited by 47
One oncogene, several vulnerabilities: EWS/FLI targeted therapies for Ewing sarcoma
Flores, G., & Grohar, P. J. (2021) · Journal of bone oncology · doi:10.1016/j.jbo.2021.100404 · Cited by 42
“like” domain of EWS/FLI directly binds and recruits the SWI/SNF chromatin remodeling complex to DNA binding sites to generate de novo enhancer regions but challenges the development of highly specific small molecule inhibitors [21,24].”
BackgroundInfluentialEwing Sarcoma: Biology-Based Therapeutic Perspectives
Potratz, J. C., Jürgens, H., Craft, A. W., & Dirksen, U. (2012) · Pediatric Hematology and Oncology · doi:10.3109/08880018.2011.627582 · Cited by 43
“CSCs are defined by a “self-renewal” capacity and are further assumed to share properties of normal stem cells such as relative quiescence, expression of multidrug resistance transporters, active DNA repair mechanisms, and resistance to apoptosis, rendering CSCs resistant to chemotherapeutic agents [91].”
BackgroundMethodInfluentialDistinct roles of hnRNPH1 low-complexity domains in splicing and transcription
Kim, G. H., & Kwon, I. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2109668118 · Cited by 36
“Collectively, our findings reveal that the hnRNPH1 C-terminal region gains an activity affecting gene expression when fused to DBDs, giving rise to the intriguing possibility that MEF2D–hnRNPH1 may contribute to the process of oncogenesis through an aberrant transcription-dependent mechanism.”
Methods for Analysis of Transcription Factor DNA-Binding Specificity In Vitro
Jolma, A., & Taipale, J. (2011) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-90-481-9069-0_7 · Cited by 48
“in vitro methods, and the differences cannot be explained by the factors described above, it is likely that the TF in question binds to DNA as a dimer with other factors, or contains additional determinants of specificity that are not present in the domain used for the in vitro analysis [35, 42, 43].”
BackgroundETV6 dependency in Ewing sarcoma by antagonism of EWS-FLI1-mediated enhancer activation
Gao, Y., He, X., Wu, X., Huang, Y., Toneyan, S., Ha, T., Ipsaro, J. J., Koo, P. K., Joshua‐Tor, L., Bailey, K. M., et al. (2023) · Nature Cell Biology · doi:10.1038/s41556-022-01060-1 · Cited by 46
Chen, C., Shanmugasundaram, K., Rigby, A. C., & Kung, A. L. (2013) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2013.02.003 · Cited by 34
Hou, C., Weidenbach, S., Cano, K. E., Wang, Z., Mitra, P., Ivanov, D. N., Rohr, J., & Tsodikov, O. V. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw761 · Cited by 35
“This DNA sequence was designed based on the previous finding that a minimum of five GGAA repeats was necessary and sufficient for the oncogenic transformation by EWS–FLI1, driven by binding to these repeats (35).”
BackgroundTheisen, E. R., Selich‐Anderson, J., Miller, K. R., Tanner, J. M., Taslim, C., Pishas, K. I., Sharma, S., & Lessnick, S. L. (2020) · Epigenetics · doi:10.1080/15592294.2020.1805678 · Cited by 34
“Binding of EWS/FLI to GGAA-μsats often results in aberrant activation of nearby genes [5,8,13].”
BackgroundSelf-citationSánchez-Molina, S., Figuerola-Bou, E., Blanco, E., Sánchez-Jiménez, M., Táboas, P., Gómez‐González, S., Ballaré, C., García-Domínguez, D. J., Prada, E., Hontecillas‐Prieto, L., et al. (2020) · Science Advances · doi:10.1126/sciadv.aba3058 · Cited by 33
“Promoter of genes that are transcriptionally activated by EWSR1-FLI1, such as FCGRT, NR0B1, CACNB2, EZH2, IGF1, NKX2-2, and HOXD11, was enriched for the H3K4me3 mark, and lacked the H3K27me3 mark, in agreement with previous data (8, 20, 23, 24) (fig.”
BackgroundResultKim, Y. R., Joo, J., Lee, H. J., Kim, C., Park, J.-C., Yu, Y. S., Kim, C. R., Lee, D. H., Cha, J., Kwon, H., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51050-0 · Cited by 38
“4d) 30,31 .”
Sannino, G., Marchetto, A., Ranft, A., Jabar, S., Zacherl, C., Rubío, R. A., Stein, S., Wehweck, F. S., Kıran, M. M., Hölting, T. L. B., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.08.002 · Cited by 34
“In fact, EWSR1-FLI1 encodes an aberrant transcription factor, which induces many of its target genes by binding to enhancer-like GGAA-microsatellites, whose activity increases with the number of consecutive GGAA-repeats [1,29].”
BackgroundPioneer factors in development and cancer
Sunkel, B. D., & Stanton, B. Z. (2021) · iScience · doi:10.1016/j.isci.2021.103132 · Cited by 33
Hong, S.-H., Tilan, J. U., Galli, S., Iżycka‐Świeszewska, E., Polk, T., Horton, M., Mahajan, A., Christian, D., Jenkins, S., Acree, R., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3345 · Cited by 38
“Microarray analyses have identified neuropeptide Y (NPY) as an EWS-FLI1 transcriptional target that is highly expressed in ES cells and released from ES tumors [16-20].”
BackgroundAdvances in the Treatment of Pediatric Bone Sarcomas
Grohar, P. J., Janeway, K. A., Maese, L. D., & Schiffman, J. D. (2017) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_175378 · Cited by 33
EWS::FLI1 and HOXD13 Control Tumor Cell Plasticity in Ewing Sarcoma
Apfelbaum, A. A., Wu, F., Hawkins, A. G., Magnuson, B., Jiménez, J. A., Taylor, S. D., Wrenn, E. D., Waltner, O. G., Pfaltzgraff, E. R., Song, J. Y., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0384 · Cited by 34
Targeting DAX-1 in embryonic stem cells and cancer
Lalli, E., & Alonso, J. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220903531454 · Cited by 33
“Preclinical experiments in xenograft mouse models for Ewing tumour have shown that lentiviral-mediated knockdown of DAX-1 expression dramatically reduces proliferation of cancerous cells [65,66].”
BackgroundFusion protein EWS-FLI1 is incorporated into a protein granule in cells
Ahmed, N. S., Harrell, L. M., Wieland, D. R., Lay, M. A., Thompson, V. F., & Schwartz, J. C. (2021) · RNA · doi:10.1261/rna.078827.121 · Cited by 34
“The FLI1 DBD in EWS-FLI1 recognizes a short DNA sequence, GGAA, and binds single sites and microsatellites of minimally 10 repeated motifs (Gangwal et al. 2008; Vo et al. 2016; Johnson et al. 2017).”
BackgroundHigh-throughput small molecule screen identifies inhibitors of aberrant chromatin accessibility
Pattenden, S. G., Simon, J. M., Wali, A., Jayakody, C. N., Troutman, J. A., McFadden, A. W., Wooten, J., Wood, C. C., Frye, S. V., Janzen, W. P., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521827113 · Cited by 35
“We recently found that, despite conservation of the ETS DNA binding domain, the fusion oncoprotein uniquely localizes to specific microsatellite regions (17, 18).”
BackgroundScheurer, M. E., Lupo, P. J., Schüz, J., Spector, L. G., Wiemels, J. L., Aplenc, R., Gramatges, M. M., Schiffman, J. D., Pombo‐de‐Oliveira, M. S., Yang, J. J. J., et al. (2018) · Pediatric Hematology and Oncology · doi:10.1080/08880018.2018.1464088 · Cited by 30
Targeting metastasis in paediatric bone sarcomas
Bull, E. C., Singh, A., Harden, A. M., Soanes, K., Habash, H., Toracchio, L., Carrabotta, M., Schreck, C., Shah, K. M., Riestra, P. V., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02365-z · Cited by 42
Showpnil, I. A., Miller, K. R., Taslim, C., Pishas, K. I., Lessnick, S. L., & Theisen, E. R. (2020) · Journal of Visualized Experiments · doi:10.3791/61564 · Cited by 30
Self-citationMo, J., Tan, K., Dong, Y., Lu, W., Liu, F., Mei, Y., Huang, H., Zhao, K., Lv, Z., Ye, Y., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02533-1 · Cited by 37
Saulnier, O., Guedri, K., Aynaud, M.-M., Chakraborty, A., Bruyr, J., Pineau, J., O’Grady, T. M., Mirabeau, O., Grossetête, S., Galvan, B., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab305 · Cited by 30
“Our study indicates that the EWS-FLI1-induced reprogramming of these cells may not only rely on transcriptional effects, in particular via genome-wide activation of GGAA microsatellites (7,8,70) but also on post-transcriptional effects, such as modulation of the pro-mesenchymal splicing program driven by RBFOX2.”
BackgroundEpigenetic Control of Translation Checkpoint and Tumor Progression via RUVBL1‐EEF1A1 Axis
Li, M., Yang, L., Chan, A., Pokharel, S. P., Liu, Q., Mattson, N., Xu, X., Chang, W., Miyashita, K., Singh, P. A., et al. (2023) · Advanced Science · doi:10.1002/advs.202206584 · Cited by 30
Uchiumi, F., Miyazaki, S., & Tanuma, S.-I. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0674-x · Cited by 31
Glutathione S-Transferases in Pediatric Cancer
Luo, W., Kinsey, M., Schiffman, J. D., & Lessnick, S. L. (2011) · Frontiers in Oncology · doi:10.3389/fonc.2011.00039 · Cited by 33
“Furthermore, EWS/FLI has been shown to transcriptionally activate some of its gene targets through GGAAcontaining microsatellite promoter elements (Gangwal et al., 2008).”
BackgroundSelf-citationAcetylation Increases EWS-FLI1 DNA Binding and Transcriptional Activity
Schlottmann, S., Erkizan, H. V., Barber-Rotenberg, J. S., Knights, C. D., Cheema, A. K., Üren, A., Avantaggiati, M. L., & Toretsky, J. A. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00107 · Cited by 31
“For reporter assays the EWS-FLI1 responsive NR0B1 microsatellite luciferase construct was used, kindly provided by Dr. Steven Lessnick (University of Utah; Gangwal et al., 2008).”
MethodTheisen, E. R., Miller, K. R., Showpnil, I. A., Taslim, C., Pishas, K. I., & Lessnick, S. L. (2019) · Genes & Cancer · doi:10.18632/genesandcancer.188 · Cited by 27
“6 kb promoter [11], 102 bp NR0B1 microsatellite [12], the 500 bp NR0B1 microsatellite [11], 10X GGAA, 20X GGAA, and 30X GGAA firefly luciferase reporter vectors are previously described [11, 33].”
BackgroundMethodInfluentialSelf-citationLi, J., Ohmura, S., Marchetto, A., Orth, M. F., Imle, R., Dallmayer, M., Musa, J., Knott, M. M. L., Hölting, T. L. B., Stein, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25553-z · Cited by 29
Buchou, C., Laud-Duval, K., van der Ent, W., Grossetête, S., Zaïdi, S., Gentric, G., Corbé, M., Müller, K., Nery, E. D., Surdez, D., et al. (2022) · Cancers · doi:10.3390/cancers14092327 · Cited by 27
Regulation of EWSR1-FLI1 Function by Post-Transcriptional and Post-Translational Modifications
Yu, L., Davis, I. J., & Liu, P. (2023) · Cancers · doi:10.3390/cancers15020382 · Cited by 27
EWS ‐ FLI 1 regulates a transcriptional program in cooperation with Foxq1 in mouse Ewing sarcoma
Shimizu, R., Tanaka, M., Tsutsumi, S., Aburatani, H., Yamazaki, Y., Homme, M., Kitagawa, Y., & Nakamura, T. (2018) · Cancer Science · doi:10.1111/cas.13710 · Cited by 27
Targeted Therapy for EWS-FLI1 in Ewing Sarcoma
Gong, H., Xue, B., Ru, J., Pei, G., & Li, Y. (2023) · Cancers · doi:10.3390/cancers15164035 · Cited by 27
“It regulates multiple proteins through its prion-like domain to tumor-specific enhancers and promotors, recruiting acetyltransferases and establishing de novo enhancers by generating H3K27ac, thus opening the chromosomal architecture, which contributes to the activation of target genes [29,30,37,39].”
BackgroundCamões, M. J., Paulo, P., Ribeiro, F. R., Barros-Silva, J. D., Almeida, M. R., Costa, V. L., Cerveira, N., Skotheim, R. I., Lothe, R. A., Henrique, R., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049819 · Cited by 24
“In order to investigate whether these ETS fusion genes have some common downstream targets, we crossed a publicly available list of all putative EWSR1-FLI1 direct target genes in ESFT (obtained by chromatin immunoprecipitation coupled with DNA microarrays) [20] with our microarray expression data on PCa with and witho…”
BackgroundMethodResultInfluentialPlotnik, J. P., & Hollenhorst, P. C. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx039 · Cited by 24
“Interestingly, the ETS binding sequence identified is similar to the GGAA repeat sequence bound by EWS-FLI1 in Ewing’s sarcoma (39).”
BackgroundSelf-citationDiessner, B. J., Weigel, B. J., Murugan, P. J., Zhang, L., Poynter, J. N., & Spector, L. G. (2020) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-20-0520 · Cited by 23
“For example, the binding affinity for EWS-FLI1, the fusion oncoprotein characteristic of Ewing sarcoma (30), depends upon the length of GGAA microsatellite repeats (51), which is polymorphic between populations of primarily European and African ancestries (52).”
BackgroundTruong, D. D., Lamhamedi-Cherradi, S.-E., Porter, R. W., Krishnan, S., Swaminathan, J., Gibson, A., Lazar, A. J., Livingston, J. A., Gopalakrishnan, V., Gordon, N. B., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-10977-1 · Cited by 28
YK-4-279 effectively antagonizes EWS-FLI1 induced leukemia in a transgenic mouse model
Minas, T. Z., Han, J., Javaheri, T., Hong, S.-H., Schlederer, M., Saygideğer-Kont, Y., Çelik, H., Mueller, K. M., Temel, I., Özdemirli, M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5520 · Cited by 23
Role of Orphan Nuclear Receptor DAX-1/NR0B1 in Development, Physiology, and Disease
Lalli, E. (2014) · Advances in Biology · doi:10.1155/2014/582749 · Cited by 25
Li, M., & Chen, C.-W. D. (2022) · Biomedicines · doi:10.3390/biomedicines10061325 · Cited by 25
“For example, ChIP-seq(chromatin immunoprecipitation coupled with high throughput sequencing)based epigenetic profiling has been conducted to investigate how EWSR1-FLI1 binds to chromatin [19,20] and how EWSR1-FLI1 establishes n appropriate chromatin state for gene expression [21,22].”
BackgroundInfluentialDeng, Q., Natesan, R., Cidre‐Aranaz, F., Arif, S., Liu, Y., Rasool, R. U., Wang, P., Mitchell-Velasquez, E., Das, C. K., Vinca, E., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110971 · Cited by 23
“As an oncogenic pioneer transcription factor, EWSR1::FLI1 binds specifically to GGAA microsatellites repeat sequence and creates de novo enhancers from a closed chromatin conformation leading to transcriptional activation of multiple oncogenes (Boulay et al., 2017; Gangwal et al., 2008; Riggi et al., 2014).”
BackgroundKodgule, R., Goldman, J. W., Monovich, A. C., Saari, T. W., Aguilar, A. R., Hall, C. N., Rajesh, N., Gupta, J., Chu, A., Ye, L., et al. (2022) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0224 · Cited by 29
“Notably, attempts to model Ewing sarcoma in mice have also yielded very limited results (55).”
BackgroundResultHallas, C., Phillipp, J., Domanowsky, L., Kah, B., & Tiemann, K. (2016) · BMC Cancer · doi:10.1186/s12885-016-2707-1 · Cited by 23
“The EWS/FLI1 fusion protein largely retains the DNA binding specificity of FLI1 [7, 8] and studying its regulatory function several genes of interest have emerged that may also play a role in SPN.”
BackgroundHigh Specificity of BCL11B and GLG1 for EWSR1-FLI1 and EWSR1-ERG Positive Ewing Sarcoma
Orth, M. F., Hölting, T. L. B., Dallmayer, M., Wehweck, F. S., Paul, T., Musa, J., Baldauf, M. C., Surdez, D., Delattre, O., Knott, M. M. L., et al. (2020) · Cancers · doi:10.3390/cancers12030644 · Cited by 26
“The fact that Caveolin-1, Cyclin-D1, NKX2-2, NR0B1 and PAX7 are known FET-ETS target genes [57,61,63,65,66] implies that not every FET-ETS target gene may serve as a highly specific auxiliary marker, since they may be also expressed at high levels in some morphological mimics.”
BackgroundOrigin of Ewing sarcoma by embryonic reprogramming of neural crest to mesoderm
Vasileva, E., Arata, C., Luo, Y., Burgos, R., Crump, J. G., & Amatruda, J. F. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116376 · Cited by 26
Uchiumi, F., Watanabe, T., & Tanuma, S.-I. (2010) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.03.009 · Cited by 22
Precision medicine in Ewing sarcoma: a translational point of view
Gargallo, P., Juan, A. D., Yáñez, Y., Dolz, S., Segura, V., Castel, V., & Cañete, A. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-020-02298-7 · Cited by 22
Phase separation of the oncogenic fusion protein EWS::FLI1 is modulated by its DNA-binding domain
Selig, E. E., Sohn, E. J., Stoja, A. P., Moreno-Romero, A. K., Akula, S., Xu, X., Bishop, A. J. R., & Libich, D. S. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2221823122 · Cited by 26
“A double - stranded DNA oligonucleotide containing 10 GGAA (GGAA 10 ) repeats known to bind FLI1 DBD in vitro (14, 47), exerted the same effect on EWS::FLI1 aggregation ( SI Appendix , Fig.”
Differential Disruption of EWS-FLI1 Binding by DNA-Binding Agents
Chen, C., Wonsey, D. R., Lemieux, M. E., & Kung, A. L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069714 · Cited by 18
“We used RPS26 and TP53 as control loci since neither are bound by EWSFLI [15] and we have shown that RPS26 and TP53 transcript levels were unaffected by actinomycin D treatment (Figure 2F).”
BackgroundMethodInfluentialYamamoto-Shiraishi, Y.-I., Higuchi, H., Yamamoto, S., Hirano, M., & Kuroiwa, A. (2014) · Developmental Biology · doi:10.1016/j.ydbio.2014.07.022 · Cited by 17
Dirksen, U., & Jürgens, H. (2010) · Future Oncology · doi:10.2217/fon.10.76 · Cited by 19
Structural Basis for Dimerization and DNA Binding of Transcription Factor FLI1
Hou, C., & Tsodikov, O. V. (2015) · Biochemistry · doi:10.1021/acs.biochem.5b01121 · Cited by 21
“In some FLI1-regulated promoters such as NR0B1, this sequence is repeated consecutively >20 times, and these repeats are essential for the oncogenic regulation by EWS-FLI1.”
BackgroundAllosteric interference in oncogenic FLI1 and ERG transactions by mithramycins
Hou, C., Mandal, A., Rohr, J., & Tsodikov, O. V. (2020) · Structure · doi:10.1016/j.str.2020.11.012 · Cited by 20
Co-targeting JAK1/STAT6/GAS6/TAM signaling improves chemotherapy efficacy in Ewing sarcoma
Yu, L., Deng, Y., Wang, X., Santos, C., Davis, I. J., Earp, H. S., & Liu, P. (2024) · Nature Communications · doi:10.1038/s41467-024-49667-2 · Cited by 23
Heisey, D. A. R., Jacob, S., Lochmann, T. L., Kurupi, R., Ghotra, M. S., Calbert, M. L., Shende, M., Maves, Y. K., Koblinski, J. E., Dozmorov, M. G., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0489 · Cited by 18
Preclinical In Vivo Modeling of Pediatric Sarcoma—Promises and Limitations
Imle, R., Kommoss, F. K. F., & Banito, A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10081578 · Cited by 17
Green, D., van Ewijk, R., Tirtei, E., Andreou, D., Baecklund, F., Baumhoer, D., Bielack, S., Botchu, R., Boye, K., Brennan, B. M. D., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0101 · Cited by 24
“The FET::ETS fusions encode oncogenic chimeric transcription factors with neomorphic features that reprogram the transcriptome (37), binding to GGAA microsatellites that become neoenhancers (38, 39), which leads to ectopic gene expression and tumor development.”
BackgroundC/EBPβ-1 promotes transformation and chemoresistance in Ewing sarcoma cells
Gardiner, J. D., Abegglen, L. M., Huang, X., Carter, B. E., Schackmann, E. A., Stucki, M., Paxton, C. N., Randall, R. L., Amatruda, J. F., Putnam, A. R., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14847 · Cited by 17
“EWS-FLI1 binds with high affinity to GGAA microsatellite repeats within the promoter regions of its target genes [5, 6].”
BackgroundSelf-citationBoulay, G., Broye, L. C., Dong, R., Iyer, S., Sanalkumar, R., Xing, Y., Buisson, R., Rengarajan, S., Naigles, B., Duc, B., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51851-3 · Cited by 18
Marques, J. G., Pavlovic, B., Ngo, Q. A., Pedot, G., Roemmele, M., Volken, L., Kisele, S., Perbet, R., Wachtel, M., & Schäfer, B. W. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-3950 · Cited by 17
Ozenberger, B. B., Li, L., Wilson, E. R., Lazar, A. J., Barrott, J. J., & Jones, K. B. (2023) · Cancers · doi:10.3390/cancers15245750 · Cited by 19
“We propose that EA1 has a novel propensity to bind TGA repeats at enhancers, similar to EWSR1::FLI1 binding of GGAA microsatellites in Ewing sarcoma [50].”
BackgroundReprogramming of mesenchymal stem cells by oncogenes
Eid, J. E., & Garcia, C. B. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2014.05.005 · Cited by 23
Circulating miR34a levels as a potential biomarker in the follow-up of Ewing sarcoma
Sciandra, M., Feo, A. D., Parra, A., Landuzzi, L., Lollini, P., Manara, M. C., Mattia, G., Pontecorvi, G., Baricordi, C., Guerzoni, C., et al. (2020) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-020-00567-2 · Cited by 18
“2017) and its activity have been reported to prime the epigenetic landscape of EWS and its aggressiveness (Sheffield et al. 2017; Grunewald et al. 2018; Gangwal et al. 2008; Johnson et al. 2017).”
BackgroundMicrosatellites with Macro-Influence in Ewing Sarcoma
Monument, M. J., Johnson, K. M., Grossmann, A. H., Schiffman, J. D., Randall, R. L., & Lessnick, S. L. (2012) · Genes · doi:10.3390/genes3030444 · Cited by 21
“Numerous investigations have demonstrated that EWS/FLI-mediated binding and activation of NR0B1 is dependent on this repetitive element [32,33,37].”
BackgroundMethodInfluentialSelf-citationStrittmatter, B. G., Jerde, T. J., & Hollenhorst, P. C. (2021) · PLoS Genetics · doi:10.1371/journal.pgen.1009708 · Cited by 19
Self-citationTargeting DNA Methylation Machinery in Pediatric Solid Tumors
Cristalli, C., & Scotlandi, K. (2024) · Cells · doi:10.3390/cells13141209 · Cited by 16
“EWS::FLI1 binds to DNA at either ETS-like consensus sites or GGAA microsatellites, which are diverted by the chimera as de novo enhancers [194–196].”
BackgroundCell Cycle Deregulation in Ewing's Sarcoma Pathogenesis
Kowalewski, A. A., Randall, R. L., & Lessnick, S. L. (2010) · Sarcoma · doi:10.1155/2011/598704 · Cited by 20
“This paper will summarize current published data associated with deregulation of the cell cycle in Ewing’s sarcoma and highlight important questions that remain to be answered.”
BackgroundSelf-citationMicrosatellite Instability in Sarcoma: Fact or Fiction?
Monument, M. J., Lessnick, S. L., Schiffman, J. D., & Randall, R. T. (2012) · ISRN Oncology · doi:10.5402/2012/473146 · Cited by 19
“EWS/FLI binds with high affinity to these GGAA-rich microsatellites, which are located roughly 1.1– 1.6 kb upstream from the transcriptional start site.”
BackgroundInfluentialSelf-citationPAX7 expression in sarcomas bearing the EWSR1-NFATC2 translocation
Charville, G. W., Wang, W., Ingram, D. R., Roy, A., Thomas, D. G., Patel, R. M., Hornick, J. L., van de Rijn, M., & Lazar, A. J. (2018) · Modern Pathology · doi:10.1038/s41379-018-0095-6 · Cited by 15
Jess, J., Sorensen, K. M., Boguslawski, E. A., Stout, M. C., Madaj, Z., Caiello, B. P., Pomaville, M. M., Wilson, E. R., Kinn-Gurzo, S. S., Parker, C. C., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3063 · Cited by 14
García‐García, L., Fernández-Tabanera, E., Cervera, S. T., de Mera, R. M. M.-F., Josa, S., González‐González, L., Rodriguez‐Martin, C., Grünewald, T. G. P., & Alonso, J. (2021) · Cancers · doi:10.3390/cancers13225668 · Cited by 13
“Several studies have demonstrated a relationship between the number of GGAArepeats, the affinity of EWSR1-FLI1 and the levels of mRNA observed in the target genes upregulated by EWSR1-FLI1 [4,36].”
Tak, Y. E., Boulay, G., Lee, L., Iyer, S., Perry, N. T., Schultz, H. T., Garcia, S. P., Broye, L. C., Horng, J. E., Rengarajan, S., et al. (2022) · Cell Genomics · doi:10.1016/j.xgen.2022.100119 · Cited by 15
Grünewald, T. G. P., & Delattre, O. (2015) · Molecular & Cellular Oncology · doi:10.1080/23723556.2015.1086853 · Cited by 12
“which is consistent with the unique ability of EWSR1-FLI1 to use GGAA-microsatellites de novo as enhancers.(9,10) Interestingly, earlier work by us and others suggested that EWSR1FLI1 drives many of its target genes through GGAA-microsatellites, and that enhancer activity increases with the number of consecutive GGAA-…”
BackgroundInfluentialMusa, J., & Grünewald, T. G. P. (2019) · Molecular & Cellular Oncology · doi:10.1080/23723556.2019.1682924 · Cited by 12
Lee, O. W., Rodrigues, C., Lin, S., Luo, W., Jones, K. M., Brown, D. W., Zhou, W., Karlins, E., Khan, S. M., Baulande, S., et al. (2023) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2023.01.017 · Cited by 12
Signaling pathways and targeted therapies in Ewing sarcoma
Jia, K., Cao, L., Yu, Y., Jing, D., Wu, W., Tine, B. A. V., & Shao, Z. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108765 · Cited by 16
Salient features of mesenchymal stem cells—implications for Ewing sarcoma modeling
Monument, M. J., Bernthal, N. M., & Randall, R. L. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00024 · Cited by 16
“It is known that EWS/FLI and related EWS/ETS fusions up-regulate numerous target genes via a Frontiers in Oncology | Pediatric Oncology February 2013 | Volume 3 | Article 24 | 2 promoter-based GGAA microsatellite response element (Gangwal et al., 2008, 2010; Guillon et al., 2009).”
BackgroundThangaretnam, K. P., Gopisetty, G., Ramanathan, P., & Rajkumar, T. (2017) · Scientific Reports · doi:10.1038/s41598-017-07482-4 · Cited by 11
Human Postmeiotic Segregation 2 Exhibits Biased Repair at Tetranucleotide Microsatellite Sequences
Shah, S. N., & Eckert, K. A. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3499 · Cited by 11
“For example, the ability of the oncogenic EWS/FLI transcription factor to modulate gene expression was recently shown to depend upon the number of consecutive GGAA/TTCC tetranucleotide motifs within a promoter-encoded microsatellite (33).”
Ebegboni, V. J., Jones, T. L., Brownmiller, T., Zhao, P. X., Pehrsson, E. C., Rajan, S. S., & Caplen, N. J. (2024) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-23-1090 · Cited by 11
Noorizadeh, R., Sax, B., Javaheri, T., Radic-Sarikas, B., Fock, V., Suresh, V., Kauer, M. O., Bykov, A., Kurija, D., Schlederer, M., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115381 · Cited by 12
So, C. L., Lee, Y. J., Vokshi, B., Chen, W., Huang, B., Sousa, E. D., Gao, Y., Portuallo, M. E., Begum, S., Jagirdar, K., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115539 · Cited by 13
Galvan, B., Ongena, L., Bruyr, J., Fettweis, G., Lucarelli, E., Lavergne, A., Mariavelle, E., O’Grady, T. M., Hassoun, Z. E. O., Claes, M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-61725-x · Cited by 10
“This reporter is speci fi cally activated by EWSR1::FLI1, because of its unique neomorphic ability to bind GGAA microsatellites 10,62 .”
Modeling fusion gene‐associated sarcoma: Advantages for understanding sarcoma biology and pathology
Tanaka, M., & Nakamura, T. (2021) · Pathology International · doi:10.1111/pin.13142 · Cited by 11
“EWS‐FLI1 recognizes the canonical ETS consensus sequence as well as the GGAA microsatellite.(47) There is a genetic predisposition of Ewing sarcoma among human populations,(48) and the etiological relevance of EWS‐FLI1 binding to GGAA repeats for progression and susceptibility of Ewing sarcoma has been reported.”
BackgroundJohnson, C. N., Xu, X., Holloway, S. P., & Libich, D. S. (2022) · Biomolecular NMR Assignments · doi:10.1007/s12104-021-10061-4 · Cited by 9
“The oncogenic activity of the EWS-FLI1 fusion is thought to partially reside with aberrant binding of the FLI1 DBD to upstream GGAA-repeat microsatellites where it acts like a pioneer factor, enabling dysregulated gene expression (Gangwal et al. 2008).”
BackgroundHölting, T. L. B., Cidre‐Aranaz, F., Matzek, D., Popper, B., Jacobi, S. J., Funk, C. M., Geyer, F. H., Li, J., Piseddu, I., Cadilha, B. L., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01641-6 · Cited by 14
“Prior reports have demonstrated that the affinity of EF1 to GGAA-msats, and thereby their enhancer activity, correlates positively with the number of consecutive GGAA-repeats [4, 7].”
BackgroundInfluentialSelig, E. E., Bhura, R., White, M. R., Akula, S., Hoffman, R. D., Tovar, C. N., Xu, X., Booth, R. E., & Libich, D. S. (2023) · Biopolymers · doi:10.1002/bip.23536 · Cited by 13
Jain, K., Henrich, I. C., Quick, L., Young, R., Mondal, S., Oliveira, A. M., Blobel, G. A., & Chou, M. M. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0505 · Cited by 10
Lin, S., Sampson, J. N., Grünewald, T. G. P., Surdez, D., Reynaud, S., Mirabeau, O., Karlins, E., Rubío, R. A., Zaïdi, S., Grossetête, S., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0237792 · Cited by 12
Extracellular Vesicles in Reprogramming of the Ewing Sarcoma Tumor Microenvironment
Pachva, M. C., Lai, H., Jia, A., Rouleau, M., & Sorensen, P. H. B. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.726205 · Cited by 13
Epidemiology of Bone and Soft Tissue Sarcomas
Lupo, P. J., Spector, L. G., O’Brien, S., Schiffman, J. D., & Hettmer, S. (2020) · Pediatric oncology · doi:10.1007/978-3-030-51160-9_1 · Cited by 15
Ubiquitin-specific proteases as therapeutic targets in paediatric primary bone tumours?
Mullard, M., Lavaud, M., Regnier, L., Tesfaye, R. A., Ory, B., Rédiní, F., & Verrecchia, F. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114797 · Cited by 12
STAG2 loss in Ewing sarcoma alters enhancer-promoter contacts dependent and independent of EWS::FLI1
Giménez-Llorente, D., Cuadrado, A., Andreu, M. J., Sanclemente-Alamán, I., Solé-Ferran, M., Rodríguez-Corsino, M., & Losada, A. (2024) · EMBO Reports · doi:10.1038/s44319-024-00303-6 · Cited by 7
“…has been proposed to act as a pioneer transcription factor that induces de novo formation of active enhancers at GGAA repeats, thereby enabling the transcription of otherwise silent genes (Gangwal et al, 2008; Riggi et al, 2014; Boulay et al, 2018; Showpnil et al, 2022; Tomazou et al, 2015).”
p300/CBP is an essential driver of pathogenic enhancer activity and gene expression in Ewing sarcoma
Godfrey, L., Regalado, B. D., Schweber, S. R., Hatton, C., Wenge, D. V., Wen, Y., Boileau, M., Wessels, M., Qi, J., Ott, C. J., et al. (2025) · EMBO Reports · doi:10.1038/s44319-025-00552-z · Cited by 9
“To promote disease formation, EWS::FLI1 exhibits a unique ability permitting it to bind in tandem to otherwise non-functional, non-conserved GGAA repetitive motifs throughout the genome (Johnson et al, 2017; Gangwal et al, 2008).”
Metadata
- Authors
- Gangwal, K., Sankar, S., Hollenhorst, P. C., Kinsey, M., Haroldsen, S. C., Shah, A. A., Boucher, K. M., Watkins, W. S., Jorde, L. B., Graves, B. J., & Lessnick, S. L.
- Affiliations
- University of Utah (US)
- Huntsman Cancer Institute (US)
- Department of Human Genetics,
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2008-07-22
- Volume
- 105
- Issue
- 29
- Pages
- 10149-10154
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC2481306
- OpenAlex
- W2027899965
- Cited by
- 297
- References
- 30
- Citations by year
- 2026: 19 · 2025: 18 · 2024: 24 · 2023: 23 · 2022: 24 · 2021: 19 · 2020: 18 · 2019: 13 · 2018: 16 · 2017: 14 · 2016: 12 · 2015: 11 · 2014: 13 · 2013: 12 · 2012: 16
- FWCI
- 13.63
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Huntsman Cancer Foundation
- Huntsman Cancer Institute
- National Institutes of Health
- National Heart, Lung, and Blood Institute (R01HL070048)
- National Cancer Institute (K08CA096755, P30CA042014)
- National Institute of General Medical Sciences (R01GM038663, R01GM059290)
- Topics
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- Ewing sarcoma, ETS transcription factors, microsatellite markers, transcription factor target genes, NR0B1, promoter binding, chromosomal translocation, gene expression regulation
- MeSH terms
- Base Sequence, DNA, Neoplasm, Humans, Molecular Sequence Data, Sarcoma, Ewing, Transcription Factors, Transfection, Oncogene Proteins, Fusion, Microsatellite Repeats, Response Elements, RNA-Binding Protein EWS, Cell Line, Tumor, Chromatin Immunoprecipitation, Proto-Oncogene Protein c-fli-1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.